RecruitingNCT02734069

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)


Sponsor

Instituto Nacional de Cancerologia de Mexico

Enrollment

132 participants

Start Date

Feb 1, 2016

Study Type

OBSERVATIONAL

Conditions

Summary

This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)
  • Candidates for treatment with carboplatin plus paclitaxel 1st line
  • Performance status (ECOG 0-2)
  • Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)
  • Normal renal ultrasound prior to initiation of treatment

Exclusion Criteria7

  • Patients with renal impairment (KDOQI 3-5)
  • Patients who do not have computed tomography study at baseline
  • Uncontrolled blood pressure (\> 140 mmHg)
  • Uncontrolled diabetes (\> 130 mg / dL)
  • Obstruction in kidney (s) or ureter (s)
  • Dehydrated patients
  • Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\> 1 month)

Interventions

DRUGCarboplatin

Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.


Locations(1)

Instituto Nacional de Cancerologia

Mexico City, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02734069


Related Trials